Karyopharm announces dosing of first patient in a phase 2 study investigating oral eltanexor in hma refractory myelodysplastic syndrome

Newton, mass., oct. 21, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the phase 2 expansion of an ongoing open-label phase 1/2 study investigating eltanexor, a novel oral, selective inhibitor of nuclear export (sine) compound, as a single-agent or in combination with approved and investigational agents in patients with several types of hematologic and solid tumor cancers (kcp-8602-801; nct02649790).
KPTI Ratings Summary
KPTI Quant Ranking